Skip to main content
Erschienen in: Journal of Endocrinological Investigation 4/2021

01.04.2021 | Original Article

Incidence of heart failure in patients with type 1 diabetes: a systematic review of observational studies

verfasst von: A. Avogaro, D. Azzolina, G. P. Fadini, I. Baldi

Erschienen in: Journal of Endocrinological Investigation | Ausgabe 4/2021

Einloggen, um Zugang zu erhalten

Abstract

Background

Heart failure (HF) is considered an important contributor to cardiovascular morbidity and mortality in diabetes mellitus. However, a precise identification of hyperglycemia as contributor for HF is missing.

Objectives

We performed a review and a meta-regression of the available observational studies on the incidence of HF in type 1 diabetes (T1D).

Data source and analysis

We conducted a systematic search of the literature on the incidence of HF in patients with T1D identifying suitable studies published between January 1970 and June 2018 using the following search string: “type 1 diabetes” AND, “heart failure” OR “cardiac failure” OR “congestive heart failure” AND “incidence” NOT “type 2 diabetes” OR “diabetes type 2”. Six observational studies were included. A random effect meta-regression model has been estimated to evaluate the incidence rate ratio (IRR) of HF in T1D compared to healthy controls.

Results

The mean ± SD age of patients with T1D was 42 ± 11 years, the mean HbA1c was 8.4 ± 0.3%, and average follow-up was 11 ± 3 years. The age-adjusted model shows an incidence rate ratio (IRR) effect of 3.18 (p < 0.001), in correspondence of the mean age at enrollment of studies involved in the analysis. A negative correlation was observed between IRR and average age.

Conclusions

This review shows that the incidence rate of HF is three times higher in patients with T1D than in controls. A careful surveillance of the risk factors for this condition should be included, since the onset of T1D may be important to reduce HF risk in these patients.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Lehrke M, Marx N (2017) Diabetes mellitus and heart failure. Am J Cardiol 120:S37–S47CrossRef Lehrke M, Marx N (2017) Diabetes mellitus and heart failure. Am J Cardiol 120:S37–S47CrossRef
2.
Zurück zum Zitat Scirica BM, Braunwald E, Raz I, Cavender MA, Morrow DA, Jarolim P et al (2015) Response to letter regarding article, “heart failure, Saxagliptin and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial”. Circulation 132:e121–e122CrossRef Scirica BM, Braunwald E, Raz I, Cavender MA, Morrow DA, Jarolim P et al (2015) Response to letter regarding article, “heart failure, Saxagliptin and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial”. Circulation 132:e121–e122CrossRef
3.
Zurück zum Zitat Fitchett D, Butler J, van de Borne P, Zinman B, Lachin JM, Wanner C et al (2018) Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME(R) trial. Eur Heart J 39:363–370CrossRef Fitchett D, Butler J, van de Borne P, Zinman B, Lachin JM, Wanner C et al (2018) Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME(R) trial. Eur Heart J 39:363–370CrossRef
4.
Zurück zum Zitat Radholm K, Figtree G, Perkovic V, Solomon SD, Mahaffey KW, de Zeeuw D et al (2018) Canagliflozin and heart failure in type 2 diabetes mellitus: results from the CANVAS Program (Canagliflozin Cardiovascular Assessment Study). Circulation 138(5):458–468CrossRef Radholm K, Figtree G, Perkovic V, Solomon SD, Mahaffey KW, de Zeeuw D et al (2018) Canagliflozin and heart failure in type 2 diabetes mellitus: results from the CANVAS Program (Canagliflozin Cardiovascular Assessment Study). Circulation 138(5):458–468CrossRef
5.
Zurück zum Zitat Bugger H, Abel ED (2014) Molecular mechanisms of diabetic cardiomyopathy. Diabetologia 57:660–671CrossRef Bugger H, Abel ED (2014) Molecular mechanisms of diabetic cardiomyopathy. Diabetologia 57:660–671CrossRef
6.
Zurück zum Zitat Rosengren A, Edqvist J, Rawshani A, Sattar N, Franzen S, Adiels M et al (2018) Excess risk of hospitalisation for heart failure among people with type 2 diabetes. Diabetologia 61:2300–2309CrossRef Rosengren A, Edqvist J, Rawshani A, Sattar N, Franzen S, Adiels M et al (2018) Excess risk of hospitalisation for heart failure among people with type 2 diabetes. Diabetologia 61:2300–2309CrossRef
7.
Zurück zum Zitat Seferovic PM, Petrie MC, Filippatos GS, Anker SD, Rosano G, Bauersachs J et al (2018) Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 20:853–872CrossRef Seferovic PM, Petrie MC, Filippatos GS, Anker SD, Rosano G, Bauersachs J et al (2018) Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 20:853–872CrossRef
8.
Zurück zum Zitat Pazin-Filho A, Kottgen A, Bertoni AG, Russell SD, Selvin E, Rosamond WD et al (2008) HbA 1c as a risk factor for heart failure in persons with diabetes: the Atherosclerosis Risk in Communities (ARIC) study. Diabetologia 51:2197–2204CrossRef Pazin-Filho A, Kottgen A, Bertoni AG, Russell SD, Selvin E, Rosamond WD et al (2008) HbA 1c as a risk factor for heart failure in persons with diabetes: the Atherosclerosis Risk in Communities (ARIC) study. Diabetologia 51:2197–2204CrossRef
9.
Zurück zum Zitat Dei Cas A, Khan SS, Butler J, Mentz RJ, Bonow RO, Avogaro A et al (2015) Impact of diabetes on epidemiology, treatment, and outcomes of patients with heart failure. JACC Heart Fail 3:136–145CrossRef Dei Cas A, Khan SS, Butler J, Mentz RJ, Bonow RO, Avogaro A et al (2015) Impact of diabetes on epidemiology, treatment, and outcomes of patients with heart failure. JACC Heart Fail 3:136–145CrossRef
10.
Zurück zum Zitat Vigili de Kreutzenberg S, Avogaro A (2013) The limited clinical value of a specific diabetic cardiomyopathy. Nutr Metab Cardiovasc Dis 23:599–605CrossRef Vigili de Kreutzenberg S, Avogaro A (2013) The limited clinical value of a specific diabetic cardiomyopathy. Nutr Metab Cardiovasc Dis 23:599–605CrossRef
11.
Zurück zum Zitat Rubler S, Dlugash J, Yuceoglu YZ, Kumral T, Branwood AW, Grishman A (1972) New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol 30:595–602CrossRef Rubler S, Dlugash J, Yuceoglu YZ, Kumral T, Branwood AW, Grishman A (1972) New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol 30:595–602CrossRef
12.
Zurück zum Zitat Konduracka E, Gackowski A, Rostoff P, Galicka-Latala D, Frasik W, Piwowarska W (2007) Diabetes-specific cardiomyopathy in type 1 diabetes mellitus: no evidence for its occurrence in the era of intensive insulin therapy. Eur Heart J 28:2465–2471CrossRef Konduracka E, Gackowski A, Rostoff P, Galicka-Latala D, Frasik W, Piwowarska W (2007) Diabetes-specific cardiomyopathy in type 1 diabetes mellitus: no evidence for its occurrence in the era of intensive insulin therapy. Eur Heart J 28:2465–2471CrossRef
14.
Zurück zum Zitat Stang A (2010) Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25:603–605CrossRef Stang A (2010) Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25:603–605CrossRef
15.
Zurück zum Zitat Becker BJ (1988) Synthesizing standardized mean-change measures. Br J Math Stat Psychol 41(2):257–278CrossRef Becker BJ (1988) Synthesizing standardized mean-change measures. Br J Math Stat Psychol 41(2):257–278CrossRef
16.
Zurück zum Zitat Thompson SG, Higgins JP (2002) How should meta-regression analyses be undertaken and interpreted? Stat Med 21:1559–1573CrossRef Thompson SG, Higgins JP (2002) How should meta-regression analyses be undertaken and interpreted? Stat Med 21:1559–1573CrossRef
17.
Zurück zum Zitat McAllister DA, Read S, Kerssens J, Livingstone S, McGurnaghan S, Jhund P et al (2018) Incidence of hospitalisation for heart failure and case-fatality among 3.25 million people with and without diabetes. Circulation 138(24):2774–2786CrossRef McAllister DA, Read S, Kerssens J, Livingstone S, McGurnaghan S, Jhund P et al (2018) Incidence of hospitalisation for heart failure and case-fatality among 3.25 million people with and without diabetes. Circulation 138(24):2774–2786CrossRef
18.
Zurück zum Zitat Rawshani A, Sattar N, Franzen S, Rawshani A, Hattersley AT, Svensson AM et al (2018) Excess mortality and cardiovascular disease in young adults with type 1 diabetes in relation to age at onset: a nationwide, register-based cohort study. Lancet 392:477–486CrossRef Rawshani A, Sattar N, Franzen S, Rawshani A, Hattersley AT, Svensson AM et al (2018) Excess mortality and cardiovascular disease in young adults with type 1 diabetes in relation to age at onset: a nationwide, register-based cohort study. Lancet 392:477–486CrossRef
19.
Zurück zum Zitat Rosengren A, Vestberg D, Svensson AM, Kosiborod M, Clements M, Rawshani A et al (2015) Long-term excess risk of heart failure in people with type 1 diabetes: a prospective case-control study. Lancet Diabetes Endocrinol 3:876–885CrossRef Rosengren A, Vestberg D, Svensson AM, Kosiborod M, Clements M, Rawshani A et al (2015) Long-term excess risk of heart failure in people with type 1 diabetes: a prospective case-control study. Lancet Diabetes Endocrinol 3:876–885CrossRef
20.
Zurück zum Zitat Larsson SC, Wallin A, Hakansson N, Stackelberg O, Back M, Wolk A (2018) Type 1 and type 2 diabetes mellitus and incidence of seven cardiovascular diseases. Int J Cardiol 262:66–70CrossRef Larsson SC, Wallin A, Hakansson N, Stackelberg O, Back M, Wolk A (2018) Type 1 and type 2 diabetes mellitus and incidence of seven cardiovascular diseases. Int J Cardiol 262:66–70CrossRef
21.
Zurück zum Zitat Lind M, Bounias I, Olsson M, Gudbjornsdottir S, Svensson AM, Rosengren A (2011) Glycaemic control and incidence of heart failure in 20,985 patients with type 1 diabetes: an observational study. Lancet 378:140–146CrossRef Lind M, Bounias I, Olsson M, Gudbjornsdottir S, Svensson AM, Rosengren A (2011) Glycaemic control and incidence of heart failure in 20,985 patients with type 1 diabetes: an observational study. Lancet 378:140–146CrossRef
22.
Zurück zum Zitat Torffvit O, Lovestam-Adrian M, Agardh E, Agardh CD (2005) Nephropathy, but not retinopathy, is associated with the development of heart disease in type 1 diabetes: a 12-year observation study of 462 patients. Diabet Med 22:723–729CrossRef Torffvit O, Lovestam-Adrian M, Agardh E, Agardh CD (2005) Nephropathy, but not retinopathy, is associated with the development of heart disease in type 1 diabetes: a 12-year observation study of 462 patients. Diabet Med 22:723–729CrossRef
23.
Zurück zum Zitat Fagan A, Asghar O, Pearce K, Stout M, Ray SG, Schmitt M et al (2015) Medalists with extreme duration of type 1 diabetes exhibit only mild diastolic dysfunction and myocardial fibrosis. Diabetes Care 38:e5–6CrossRef Fagan A, Asghar O, Pearce K, Stout M, Ray SG, Schmitt M et al (2015) Medalists with extreme duration of type 1 diabetes exhibit only mild diastolic dysfunction and myocardial fibrosis. Diabetes Care 38:e5–6CrossRef
24.
Zurück zum Zitat Helve J, Sund R, Arffman M, Harjutsalo V, Groop PH, Gronhagen-Riska C et al (2018) Incidence of end-stage renal disease in patients with type 1 diabetes. Diabetes Care 41:434–439CrossRef Helve J, Sund R, Arffman M, Harjutsalo V, Groop PH, Gronhagen-Riska C et al (2018) Incidence of end-stage renal disease in patients with type 1 diabetes. Diabetes Care 41:434–439CrossRef
25.
Zurück zum Zitat Sedgwick P (2015) Understanding the ecological fallacy. BMJ 351:h4773CrossRef Sedgwick P (2015) Understanding the ecological fallacy. BMJ 351:h4773CrossRef
26.
Zurück zum Zitat Diabetes C, Complications Trial /Epidemiology of Diabetes I, Complications Study Research G (2016) Intensive diabetes treatment and cardiovascular outcomes in type 1 diabetes: the DCCT/EDIC study 30-year follow-up. Diabetes Care 39:686–693CrossRef Diabetes C, Complications Trial /Epidemiology of Diabetes I, Complications Study Research G (2016) Intensive diabetes treatment and cardiovascular outcomes in type 1 diabetes: the DCCT/EDIC study 30-year follow-up. Diabetes Care 39:686–693CrossRef
27.
Zurück zum Zitat Nichols GA, Gullion CM, Koro CE, Ephross SA, Brown JB (2004) The incidence of congestive heart failure in type 2 diabetes: an update. Diabetes Care 27:1879–1884CrossRef Nichols GA, Gullion CM, Koro CE, Ephross SA, Brown JB (2004) The incidence of congestive heart failure in type 2 diabetes: an update. Diabetes Care 27:1879–1884CrossRef
28.
Zurück zum Zitat Jaiswal M, Divers J, Urbina EM, Dabelea D, Bell RA, Pettitt DJ et al (2018) Cardiovascular autonomic neuropathy in adolescents and young adults with type 1 and type 2 diabetes: the SEARCH for Diabetes in Youth Cohort Study. Pediatr Diabetes 19:680–689CrossRef Jaiswal M, Divers J, Urbina EM, Dabelea D, Bell RA, Pettitt DJ et al (2018) Cardiovascular autonomic neuropathy in adolescents and young adults with type 1 and type 2 diabetes: the SEARCH for Diabetes in Youth Cohort Study. Pediatr Diabetes 19:680–689CrossRef
29.
Zurück zum Zitat Lorenzoni G, Azzolina D, Lanera C, Brianti G, Gregori D, Vanuzzo D et al (2018) Time trends in first hospitalization for heart failure in a community-based population. Int J Cardiol 271:195–199CrossRef Lorenzoni G, Azzolina D, Lanera C, Brianti G, Gregori D, Vanuzzo D et al (2018) Time trends in first hospitalization for heart failure in a community-based population. Int J Cardiol 271:195–199CrossRef
30.
Zurück zum Zitat Harding JL, Pavkov ME, Magliano DJ, Shaw JE, Gregg EW (2018) Global trends in diabetes complications: a review of current evidence. Diabetologia 62(1):3–16CrossRef Harding JL, Pavkov ME, Magliano DJ, Shaw JE, Gregg EW (2018) Global trends in diabetes complications: a review of current evidence. Diabetologia 62(1):3–16CrossRef
31.
Zurück zum Zitat Bank IEM, Gijsberts CM, Teng TK, Benson L, Sim D, Yeo PSD et al (2017) Prevalence and clinical significance of diabetes in asian versus white patients with heart failure. JACC Heart Fail 5:14–24CrossRef Bank IEM, Gijsberts CM, Teng TK, Benson L, Sim D, Yeo PSD et al (2017) Prevalence and clinical significance of diabetes in asian versus white patients with heart failure. JACC Heart Fail 5:14–24CrossRef
Metadaten
Titel
Incidence of heart failure in patients with type 1 diabetes: a systematic review of observational studies
verfasst von
A. Avogaro
D. Azzolina
G. P. Fadini
I. Baldi
Publikationsdatum
01.04.2021
Verlag
Springer International Publishing
Erschienen in
Journal of Endocrinological Investigation / Ausgabe 4/2021
Elektronische ISSN: 1720-8386
DOI
https://doi.org/10.1007/s40618-020-01368-5

Weitere Artikel der Ausgabe 4/2021

Journal of Endocrinological Investigation 4/2021 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.